CStone Pharmaceuticals Co Ltd (CStone Pharmaceuticals) is a biopharmaceutical company. It develops and commercializes immuno-oncology and precision medicine to address the unmet medical needs of cancer patients. The company’s pipeline product portfolio includes Ivosidenib (CS3010) for the treatment of acute myeloid leukemia (AML); CS1001 to treat solid tumors; Avapritinib (CS3007) for the treatment of liver diseases; CS1002, CS1003, CS3006, CS3003, CS3002 to treat solid tumors. CStone Pharmaceuticals operates clinical research institutions for developing anti-cancer drugs. The company's partners include Agios Inc, Blueprint Medicines Corp and WuXi Biologics. CStone Pharmaceuticals is headquartered in Shanghai, China.
Headquarters
China
Address
21st Floor, No. 399, No. 399, West Haiyang Road, New Bund Times Square, Pudong New Area, Shanghai, 200126
Website
www.cstonepharma.com
Telephone
86 021 60335000
No of Employees
230
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
2616 (HKG)
Revenue (2022)
$65.6M
-3.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
59.3%
(2022 vs 2021)
Market Cap*
$140.9M
Net Profit Margin (2022)
XYZ
57.8%
(2022 vs 2021)
* As of and is in US$
CStone Pharmaceuticals Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | AYVAKIT |
| CS3010 -Acute Myeloid Leukemia (AML) | TIBSOVO |
| CS1001- Solid Tumors | GAVRETO |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In May, the company announced to terminate Licensing agreement with EQRx on sugemalimab and nofazinlimab and will regain the development and commercialization rights of the tumor immunotherapy drug PD-L1 antibody sugemalimab and PD-1 antibody nofazinlimab. |
| 2023 | Regulatory Approval | In May, Servier announced that the European Commission approved the targeted therapy Tuosuvo (Avonib Tablets ) Two indications, Tosuvo combined with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) adults carrying isocitrate dehydrogenase-1 (IDH1) R132 mutation. |
| 2022 | Contracts/Agreements | In November, the company launched the global The first-of-its-kind IDH1 inhibitor Tuoshuwo ( Avonib Tablets) Worun Hope-Patient Rescue Project. |
Competitor Comparison
| Key Parameters | CStone Pharmaceuticals Co Ltd | Akeso Inc | Lee's Pharmaceutical Holdings Ltd | Zhongzhu Healthcare Holding Co Ltd | Alphamab Oncology |
|---|---|---|---|---|---|
| Headquarters | China | China | Hong Kong | China | China |
| City | Shanghai | Zhongshan | HongKong | Zhuhai | Suzhou |
| State/Province | Shanghai | Guangdong | - | Guangdong | Jiangsu |
| No. of Employees | 230 | 2,778 | 1,060 | 1,420 | 435 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jianxin Yang | Senior Vice President; Chief Executive Officer; Chief Medical Officer; Director | Executive Board | 2016 | 59 |
| Ngai Chiu Archie Tse | Chief Scientific Officer; Senior Vice President | Senior Management | 2018 | 56 |
| Josh Zhou | General Manager - Greater China; Head - Commercial | Senior Management | 2022 | 42 |
| Jun Cheng | Vice President - Finance | Senior Management | 2022 | 43 |
| Michael J. Choi | Chief Business Officer | Senior Management | 2021 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward